



## INVITATION

### LAWG Innovation Club

### The Future of Oncology Treatment in Terms of Medicines' Policy and Horizon Scanning in Lithuania

20 September 2018

Gedimino av. 3, The Lithuanian Academy of Science, Vilnius

On behalf of the Pharmaceutical Committee of American Chamber of Commerce "Local American Working Group" we are pleased to invite you to the LAWG Innovation Club meeting – round table discussion, which will be held on 20 September 2018, Gediminas av. 3 (The Lithuanian Academy of Sciences).

The topic of this meeting – "The Future of Oncology Treatment in Terms of Medicines' Policy and Horizon Scanning in Lithuania". Every year around 18 000 people in Lithuania are diagnosed with oncological disease. The World Health Organization (WHO) predicts that in 2040, oncological diseases will be the most common cause of death in the world. Even though treatment methods are being improved and more and more patients recover, not all people with this disease receive state-guaranteed treatment in Lithuania, in particular, the medicinal product necessary to save their life and health. According to the representatives of Lithuanian oncology institutions and patients' organisations, Lithuanian health system no longer has any other way but adapting to the needs of today's oncologic patient.

Taking into account the above-mentioned, during the meeting we will discuss the current situation of the oncological diseases with regard to medical reimbursed treatment, the therapeutic value evaluation criteria of medicinal products for oncological diseases considered for inclusion in the list of reimbursable medicinal products as well as try to answer the questions how such medicinal products will be evaluated in the future, in particular when there are no available clinical data, and talk about future trends and forecasts in this area worldwide.

- |               |                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:00 – 13:20 | <b>Dr Kristina Garuolienė</b> , Vice-Minister of the Ministry of Health of the Republic of Lithuania, Chairman of Diseases, Medicinal Products and Medical Aids Compensation Commission, Lecturer at Department of Pathology, Forensic Medicine and Pharmacology (Vilnius University, Faculty of Medicine)                                                                                           |
| 13:20 – 13:40 | <b>Dr Oriol de Sola-Morales</b> (Spain), NDA HTA Advisory Board Member; Universitat Internacional Catalunya (UIC) – Associate professor in Health Economics; Member of the Research Advisory Council (Consell Assessor de la Recerca), Department of Health, Generalitat de Catalunya; HITT – Health Institute for Technology Transfer, Founding Partner                                             |
| 13:40 – 14:00 | <b>Prof. Dr (HP) Feliksas Jankevičius</b> , Head of National Cancer Institute, Professor at Department of Gastroenterology, Nephrology and Abdominal Surgery (Vilnius University, Faculty of Medicine)                                                                                                                                                                                               |
| 14:00 – 14:20 | <b>Dr Mark Verrill</b> (UK), Head of the Department of Medical Oncology at the Northern Centre for Cancer Care at the Freeman Hospital, Newcastle upon Tyne. Active in clinical research with an extensive breast trial portfolio in NCCC and numerous publications resulting from clinical studies                                                                                                  |
| 14:20 – 14:40 | <b>Gintautas Barcys</b> , Head of State Medicines Control Agency of Lithuania<br><b>Dr Andrius Vagoras</b> , expert of the project "Creation and implementation of the system of healthcare technology assessment, related to pharmaceuticals" at the State Medicines Control Agency of Lithuania                                                                                                    |
| 14:40 – 15:00 | <b>Dr Valdas Pečeliūnas</b> , physician haematologist of Haematology, Oncology and Transfusion Centre, Senior ordinator of Autologous Transplantation Unit (Vilnius University Hospital Santaros Klinikos). The field of scientific research includes multiple myeloma and other diseases of plasmatic cells. Member of Lithuanian Society of Haematology and European Association of Haematologists |
| 15:00 – 15:45 | Participants' statements, discussion                                                                                                                                                                                                                                                                                                                                                                 |
- The moderator of the discussion – attorney-at-law, head of LAWG **Rūta Pumputienė**

### **About LAWG Innovation Club**

*LAWG undertakes to bring together pharmaceutical industry representatives, health policy analysts, health policy makers, patients' representatives, healthcare practitioners for a closed round table discussion. Most complicated health-related topics will be discussed and representatives of industry, patients, healthcare practitioners and other specialists will submit proposals to the Ministry of Health to ensure the best, most effective treatment and availability of medicines for patients in Lithuania.*